1차 출처 기록
Halozyme Therapeutics는 Elektrofi를 현금 7억 5천만 달러 선불금과 제품 규제 승인에 따라 최대 3건의 5천만 달러 마일스톤 지급을 포함한 합병 계약 및 계획을 체결했습니다. 이번 인수는 반독점 심사를 포함한 관례적인 종결 조건의 적용을 받습니다.
8-K false 0001159036 0001159036 2025-09-30 2025-09-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 30, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 12390 El Camino Real San Diego California 92130 (Address of principal executive offices) (Zip Code) (858) 794-8889 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the ap